Table 2.
Tumor characteristics
| Tumor characteristics | Overall n = 70 | 65–74 years n = 27 | 75+ years n = 43 | p value |
|---|---|---|---|---|
| Stagea | ||||
| DCIS % (n) | 23 % (16) | 30 % (8) | 19 % (8) | 0.43 |
| Stage I % (n) | 60 % (42) | 52 % (14) | 65 % (28) | |
| Stage II % (n) | 10 % (7) | 7 % (2) | 12 % (5) | |
| Stage III % (n) | 4 % (3) | 4 % (1) | 5 % (2) | |
| Stage IV % (n) | 1 % (1) | 4 % (1) | 0 | |
| Phyllodes tumor % (n) | 1 % (1) | 4 % (1) | 0 | |
| Estrogen receptor (ER), DCIS (n = 16) | ||||
| ER positive | 81 % (13) | 88 % (7) | 75 % (6) | 0.58 |
| ER negative | 13 % (2) | 13 % (1) | 13 % (1) | |
| Unknown | 6 % (1) | 0 | 13 % (1) | |
| Estrogen receptor, stages I–IV (n = 53) | ||||
| ER positive | 94 % (50) | 94 % (17 of 18) | 94 % (33 of 35) | 0.98 |
| ER negative | 6 % (3) | 6 % (1 of 18) | 6 % (2 of 35) | |
| Progesterone Receptor (PR), stages I–IV (n = 53)b | ||||
| PR positive | 79 % (42) | 67 % (12 of 18) | 86 % (30 of 35) | 0.16 |
| PR negative | 2 % (1) | 6 % (1) | 0 | |
| Unknown | 19 % (10) | 28 % (5) | 14 % (4) | |
| Tumor size, stages I–IV (n = 53) | 0.35 TOTb | |||
| 1 cm or less | 53 % (28) | 61 % (11) | 49 % (17) | |
| >1–2 cm or less | 28 % (15) | 22 % (4) | 31 % (11) | |
| >2–5 cm or less | 15 % (8) | 17 % (3) | 14 % (5) | |
| >5 cm | 4 % (2) | 0 | 6 % (2) | |
| DCIS treatment (n = 16) | ||||
| Mastectomy | 38 % (6) | 38 % (3) | 38 % (3) | 1.0 |
| Lumpectomy and radiotherapy | 50 % (8) | 50 % (4) | 50 % (4) | |
| Lumpectomy alone | 13 % (2) | 13 % (1) | 13 % (1) | |
| Received hormonal therapy, DCIS, if ER+ (n = 14) | 6 % (1) | 0% | 13 % (1) | 0.30 |
| Stage I–III treatment (n = 52) | ||||
| Mastectomy | 21 % (11) | 18 % (3 of 17) | 23 % (8 of 35) | 0.28 |
| Lumpectomy plus radiotherapy | 71 % (37) | 82 % (14 of 17) | 66 % (23 of 35) | |
| Lumpectomy alone | 8 % (4) | 0 % (0) | 11 % (4 of 35) | |
| Received hormonal therapy, stages I–IV, if ER+ (n = 50) | 74 % (37) | 100 % (17) | 61 % (20 of 33) | 0.003 |
| Received chemotherapy, stages I–IV (n = 53) | 15 % (8) | 44 % (8 of 18) | 0 % (0 of 35) | <0.001 |
a
TOT test of trend
b
None of the estrogen receptor negative tumors were known to be progesterone receptor positive
p values <0.05 are in bold